Abstracts Archive - Page 1991 of 2607 - ACR Meeting Abstracts

Abstract Number: 1804 • 2015 ACR/ARHP Annual Meeting
Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis
Chi Chiu Mok¹, Kar Li Chan¹, Sau Mei Tse¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the association between the metabolic syndrome (MetS) and vascular events, end stage renal failure (ESRF) and mortality in patients with SLEMethods: Patients…
Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Jeffrey Riggs¹, Brian Naiman², Jing Zhang¹, Yan Xu¹, Inna Vainshtein³, Carl Hay¹, Kevin Schifferli¹, Pina Cardarelli⁴, Meina Liang⁵, Lorin Roskos⁶, Jane Connor⁷, Roland Kolbeck⁸, Anthony Coyle⁹ and Michael Fung¹, ¹MedImmune LLC, Gaithersburg, MD, ²Research, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Hayward, CA, ⁴Medarex, Sunnyvale, CA, ⁵PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, ⁶MedImmune LLC, Mountain View, CA, ⁷Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ⁸Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, ⁹Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…
Abstract Number: 1806 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok¹, Hannah Penn², Sau Mei Tse¹, Loralie Langman², Kar Li Chan¹ and Paul Jannetto³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the relationship between the serum hydroxychloroquine (HCQ) concentration and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients.Methods:…
Abstract Number: 1807 • 2015 ACR/ARHP Annual Meeting
Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus
April Barnado, Annette M. Oeser, Yahua Zhang, Jens Titze, C. Michael Stein and Cecilia P. Chung, Medicine, Vanderbilt University, Nashville, TN
Background/Purpose: The prevalence of hypertension is increased in patients with systemic lupus erythematosus (SLE). Sodium (Na+) and potassium (K+) intake are modifiable determinants of blood…
Abstract Number: 1808 • 2015 ACR/ARHP Annual Meeting
Exercise Is Associated with Improved Cardiometabolic Risk Factors in Patients with SLE
Michelle J. Ormseth¹, Annette M. Oeser² and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased prevalence of insulin resistance and the metabolic syndrome. Exercise has been shown to improve insulin…
Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Angela Pakozdi¹, Ravindra Rajakariar², Muhammad Magdi Yaqoob² and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
Abstract Number: 1810 • 2015 ACR/ARHP Annual Meeting
A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort
Vaneet K. Sandhu¹, Mariko L. Ishimori¹, Janet Wei², Louise Thomson², Daniel Berman², Jay Schapira², Noel Bairey Merz², Daniel Wallace³ and Michael Weisman³, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: To investigate serial changes in the prevalence of coronary microvascular dysfunction and coronary artery disease (CAD) by cardiac imaging in a cohort of SLE…
Abstract Number: 1811 • 2015 ACR/ARHP Annual Meeting
Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
April Jorge¹, Apinya Lertratanakul², Julia (Jungwha) Lee³, William Pearce¹, David McPherson⁴, Trina Thompson⁵, Emma Barinas-Mitchell⁶ and Rosalind Ramsey-Goldman¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴University of Texas Health Science Center, Houston, TX, ⁵Saint Francis University, Ebensburg, PA, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Women with SLE have an increased incidence of premature cardiovascular disease (CVD). Depression is also common among SLE patients. A relationship between depression and…
Abstract Number: 1812 • 2015 ACR/ARHP Annual Meeting
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Tomonori Ishii¹, Yoshiya Tanaka², Atsushi Kawakami³, Kazuyoshi Saito², Kunihiro Ichinose⁴, Yuko Shirota⁵, Hiroshi Fujii⁵, Yoko Fujita⁶, Yukiko Kamogawa⁵, Tomoaki Machiyama⁵, Kanae Akita⁵ and Hideo Harigae⁵, ¹Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…
Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Jie An¹, Joshua Woodward², Mark Minie³, YuFeng Peng⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
Abstract Number: 1814 • 2015 ACR/ARHP Annual Meeting
Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic infections such as…
Abstract Number: 1815 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Laura Durcan¹, William Clarke², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²Department of Pathology, Clinical Chemistry., Johns Hopkins University Hospital, Baltimore, MD, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Hydroxychloroquine is at the cornerstone of systemic lupus erythematosus (SLE) management. It is used for both its effect on disease activity and long-term benefits.…
Abstract Number: 1816 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Yun Jung Choi¹, Won-Seok Lee², Myong-Joo Hong³, Chang-Hoon Lee⁴, Myeung Su Lee⁵, Young Sun Suh⁶, Sang-Il Lee⁷ and Wan-Hee Yoo⁸, ¹Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, JeonJu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, ³Internal Medicine, Presbyterian Medical center, Jeonju, South Korea, ⁴Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁵Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁸Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea
Background/Purpose: Lupus nephritis(LN) is one of the significant cause of mortality in patients with systemic lupus erythematosus. Tacrolimus, a calcineurin inhibitor widely used in prevention…
Abstract Number: 1817 • 2015 ACR/ARHP Annual Meeting
Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain
Jaime Shaw¹, Mariko L. Ishimori², Vaneet K. Sandhu², Behzad Sharif³, Louise Thomson⁴, Debiao Li¹, Jay Schapira⁴, Daniel Wallace³, Noel Bairey Merz⁴, Michael Weisman³ and Daniel Berman⁴, ¹Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: SLE patients often exhibit signs and symptoms of cardiac ischemia with an overall increased prevalence of coronary artery disease (CAD), microvascular dysfunction and myocarditis…
Abstract Number: 1818 • 2015 ACR/ARHP Annual Meeting
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Shubhasree Dutta Choudhury¹, Ann Biehl², Maryam Ghaderi-yeganeh³, Zerai Manna⁴ and Sarfaraz Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases2, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institutes of Health Clinical Center Department of Pharmacy, National Institutes of Health, Bethesa, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Immune dysregulation associated with SLE leads to a substantially high background risk of infection. This risk of infection further increases with the use of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].